We are live on ! Find out more
TCON

TRACON Pharmaceuticals, Inc. Common Stock

Delisted

TCON was delisted on the 27th of June, 2024.

27 hedge funds and large institutions have $2.9M invested in TRACON Pharmaceuticals, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

16% less funds holding

Funds holding: 3227 (-5)

25% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 4

56% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 9

85% less capital invested

Capital invested by funds: $18.8M → $2.9M (-$15.9M)

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
27
Holders Change
-5
Holders Change %
-15.63%
% of All Funds
0.42%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
4
Increased
3
Reduced
4
Closed
9
Calls
$11K
Puts
Net Calls
+$11K
Net Calls Change
-$98K
Name Holding Trade Value Shares
Change
Change in
Stake
Susquehanna International Group
26
Susquehanna International Group
Pennsylvania
-$79.1K -2,094 Closed
Citadel Advisors
27
Citadel Advisors
Florida
-$37.8K -999 Closed
XSC
28
X-Square Capital
Puerto Rico
-$34K -887 Closed
Jane Street
29
Jane Street
New York
-$32.1K -849 Closed
Two Sigma Advisers
30
Two Sigma Advisers
New York
-$19.5K -515 Closed
UBS Group
31
UBS Group
Switzerland
-$11.4K -301 Closed
ASN
32
Advisory Services Network
Georgia
-$3.78K -100 Closed
Simplex Trading
33
Simplex Trading
Illinois
-$402 -22 Closed
TWA
34
TCI Wealth Advisors
Arizona
-$189 -5 Closed
Royal Bank of Canada
35
Royal Bank of Canada
Ontario, Canada
+$256 +14 New

TCON Hedge Fund Activity: Q2 2023 in Review

27 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in TRACON Pharmaceuticals, Inc. Common Stock (TCON) for Q2 2023, worth a combined $2.9M — down 85% from $18.8M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of TCON and 4 opened new positions — a net loss of 5 holders — while 4 trimmed existing stakes and 3 added.

The largest buyer was Vanguard Group, adding an estimated $139K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $79.1K sold.

  • 27 institutional investors held TRACON Pharmaceuticals, Inc. Common Stock (TCON) as of Q2 2023, down from 32 in Q1 2023.
  • Funds reported $2.9M of TRACON Pharmaceuticals, Inc. Common Stock stock for Q2 2023, down 85% quarter-over-quarter.
  • 4 funds opened new TRACON Pharmaceuticals, Inc. Common Stock positions in Q2 2023 and 9 closed out, a net change of -5 holders.
  • The largest TRACON Pharmaceuticals, Inc. Common Stock buyer in Q2 2023 was Vanguard Group, an estimated $139K added.
  • The largest TRACON Pharmaceuticals, Inc. Common Stock seller in Q2 2023 was Susquehanna International Group, an estimated $79.1K sold.

Based on aggregated 13F filings for Q2 2023.